Brief: BioInvent And Transgene Presents Data About BT-001
03/03/2020 07:49
March 3 (Reuters) - BioInvent International AB BINV.ST :
* BIOINVENT AND TRANSGENE PRESENTS DATA ABOUT BT-001
* BOTH ONCOLYTIC AND ANTI-CTLA4 THERAPEUTIC STRATEGIES THAT
SUPPORT BT-001 HAVE SHOWN ACTIVITY IN HUMANS BASED ON THEIR
ABILITY TO INDUCE SUBSTANTIAL CHANGE IN TUMOR MICROENVIRONMENT
AND ANTITUMORAL ACTIVITY
* TRANSGENE AND BIOINVENT HAVE SUBMITTED FIRST APPLICATION
FOR
CLINICAL TRIAL OF BT-001, AND A FIRST-IN-HUMAN TRIAL IS EXPECTED
TO START BEFORE END OF 2020 IN EUROPE AND THE UNITED STATES
Source text for Eikon: ID:nWkr9Dd1Vh
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))